Senior Software Engineer, Asimov
Intelligent genetic design platform
Be an early applicant
Intelligent genetic design platform
21-100 employees
Be an early applicant
21-100 employees
Company mission
To empower the genetic designers who are building the future.
Role
Who you are
- You have 6+ years of experience in software development
- You have technical expertise in Python 3, Strawberry, SQLAlchemy, GraphQL, Elasticsearch, Docker
- You have a sense of urgency and a desire to work on challenging technical projects
- You have the ability to navigate the ambiguity of building something that is first-of-its-kind
- You have multiple years of experience building and scaling systems to production-level workloads
- You possess sound technical judgment that considers quality, performance, and product stage
- You have a passion for joining a startup where autonomy, passion to learn, and excitement to engineer biology take precedence over process and ego
- Experience developing computer-aided design software and/or scientific software applications is desired, though not required
What the job involves
- We are looking for an experienced Senior Software Engineer to join our dynamic Software Engineering team
- At Asimov, we are creating a state-of-the-art platform to program living cells, named Kernel, that allows bioengineers to design, build, and debug genetic systems at scale
- You will be part of an interdisciplinary team that works directly with our internal group of scientists, synthetic biologists, and computational biologists as well as your teammates in software engineering and product
- Design, build, and maintain software tools that are used by bioengineers to advance the design and manufacture of biologics and gene therapies
- Directly shape the software architecture and be involved in the long-term product direction
- Work with a modern backend stack (Python 3, Strawberry, SQLAlchemy)
- Develop data models and schemas for the complex domain of biology
- Be part of an on-call rotation to support the software you’ve helped develop
- Interface directly with members of the synthetic biology team to identify and prioritize potential improvements to software systems
- Contribute to Asimov’s technology platform, direction, and culture
Our take
Despite the many recent breakthroughs in medicine, drug manufacturing remains a lengthy and costly process that is difficult to scale. Asimov seeks to combat this with its intelligent design suite for synthetic biologists, that leverages computer-aided design to help design, simulate, and optimise genetic systems more reliably.
Asimov's platform consists of a fully integrated suite of cells, genes, and software that can be implemented in every step of the therapeutics creation process from initial design through to analysis. By accelerating the speed at which biologists can test and improve their drugs, the company has hopes to help bring innovative treatments to market faster and thus advance the standard of treatment for patients.
Having secured considerable funding, Asimov is looking to scale its business in biologics, advanced cell/gene therapies, and RNA. It will also use the investment to expand research and development into new areas of synthesis, as well as grow its team.
Steph
Company Specialist at Welcome to the Jungle
Company
Funding (last 2 of 3 rounds)
Jan 2023
$175m
SERIES B
Dec 2019
$25m
SERIES A
Total funding: $204.7m
Company HQ
West Fens, Boston, MA
Leadership
Chris Voigt
(Co-Founder)Board Member at the Novo Nordisk Foundation, MIT Professor, and Co-Founder of Pivot Bio.
Douglas Densmore
(Co-Founder)Professor at Boston University. Previously co-founded BioSens8 and Lattice Automation.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job